glp 1 addiction studies GLP-1 receptor agonists show promise in treating substance use disorders How GLP-1 Can Help in

Not evaluated by the FDA

GLP-1 medications are also now being studied in individuals with metabolic liver disease, peripheral artery disease and neurodegenerative disorders, such as Alzheimers disease and Parkinsons disease

(First Trust or FTA), a leading provider of exchange-traded funds (ETFs) and outcome-based strategies, announced the launch of three new actively managed ETFs this week: FT Vest Growth Strength & Target Income ETF (Nasdaq: FGSI) launched June 26, 2025, and seeks to provide current income that, when annualized, is approximately 8% above the annual dividend yield of the S&P 500 Index 1 by investing primarily in U.S

solo estn para uso tpico, que es mucho menos eficaz actualmente se ha solicitado autorizacin a la Agencia Espaola de Medicamentos y Productos Sanitarios (AEMPS) pero todava no hay resolucin al respecto

Although these otherwise healthy patients do not experience proteinuria or any major increase in their relative risk of all-cause mortality, the high prevalence of chronic diseases like diabetes, obesity, and hypertension in the aged population exacerbates this natural aging-related decline in eGFR [68]

Rao X, Zhao S, Braunstein Z, Mao H, Razavi M, Duan L, et al